← Back to headlines
Kyverna Therapeutics Reports Q4 GAAP EPS of -$0.80, Beating Estimates
Kyverna Therapeutics announced its financial results, reporting a GAAP Earnings Per Share (EPS) of -$0.80, which surpassed analyst estimates by $0.05.
26 Mar, 20:36 — 26 Mar, 20:36
Sources
Showing 1 of 1 sources
Related Stories
Trump's Signature to Appear on New US Currency for 250th Anniversary
47m ago
Tether Hires KPMG and PwC for Auditing and Internal Systems Ahead of US Expansion
49m ago
Worksport Targets $35M–$42M Revenue by 2026, Boosted by Product Launches and Margin Growth
50m ago
Icelandic Media Personality Urges Professionals to Keep Money Abroad
52m ago